Table 1

Percent TUNEL-positive cells in IFN-α2 and IFN-β treated cell lines of different histopathologies

All cell lines except Daudi and Jurkat were treated with IFN-α2 and IFN-β (1000 units/ml) for 96 h. Daudi cells and Jurkat, being most sensitive to antigrowth effects of IFNs (IC50 > 20 units/ml), were treated with 500 units/ml IFNs. Cells were fixed in paraformaldehyde and stained for TUNEL assay as described in “Materials and Methods.” Untreated cells were processed in parallel as controls.
HistologyCell lineControlIFN-α2IFN-β
MelanomaA3751.20.61.5
MelanomaWM91.20.733.5
MelanomaGuilliams0.80.311.0
MelanomaFemX0.52.622.6
MelanomaMinors1.82.616
Breast carcinomaMCF71.75.29.6
Breast carcinomaMDA-MB2313.12.011.0
Breast carcinomaT47D2.22.55.4
HematopoieticDaudi1.45.81.9
HematopoieticJurkat2.61.61.6
HematopoieticU9370.81.74.0
Ovarian carcinomaNIHovcar39.011.426.5
Cervical carcinomaHela1.21.11.3
Renal cell carcinomaACHN0.91.437.5